Craif's Urine Cancer Test 'miSignal Scan' Wins Communication Contribution Award at the 38th 'Hit Product & Topic Product Awards' Hosted by Drug Magazine

Craif Inc., a bio-AI startup (Location: Shinjuku-ku, Tokyo; CEO: Ryuichi Onose), is pleased to announce that its urine cancer test, 'miSignal Scan,' has won the 'Topic Award: Communication Contribution Award' at the 38th 'Hit Product & Topic Product Awards,' organized by Drug Magazine Co., Ltd. and the healthcare wholesalers' association 'Yachiyokai,' and supported by the Japan Association of Chain Drug Stores.

About the 'Hit Product & Topic Product Awards'

The 'Hit Product & Topic Product Awards' is one of the industry's most prestigious award events, hosted by Drug Magazine Co., Ltd. and Yachiyokai (*1), and supported by the Japan Association of Chain Drug Stores.

The award winners are selected through voting by 10 wholesale companies belonging to Yachiyokai and leading retail companies such as drugstores and pharmacies nationwide. The aim is to promote tripartite communication among manufacturers, distributors, and retailers (drugstores) and to foster the healthy development of the self-care market.

Through the discerning 'eye' of industry professionals, the awards fairly evaluate and honor new products that capture consumer needs and innovative marketing activities. It serves as a 'compass' indicating market trends and growth directions.

*1 Yachiyokai: A healthcare wholesalers' association that bulk-purchases the 'Weekly Drug Topics' published by Drug Magazine Co., Ltd. and provides it to pharmacies and drugstores as part of its information service.

About This Award

The 'Topic Award: Communication Contribution Award,' which 'miSignal Scan' received, is given to products that, in addition to sales performance, have generated new demand, conducted innovative promotions, created buzz on social media, and had a significant impact on the market.

The award ceremony will be held on Friday, April 23, 2026, at Hotel Tokyo Garden Palace (Yushima, Tokyo).

◼️ About the Award-Winning Product 'miSignal Scan'

'miSignal Scan' is a test that extracts microRNA from urine and analyzes it with AI to evaluate the risk for 10 types of cancer*, including pancreatic cancer, by cancer type, from Stage 1. The test can be performed without any physical burden by simply collecting a urine sample.

For more details, please visit the website.

https://misignal.jp/

'miSignal Scan' is not a medical device. It determines risk by statistically calculating analyzed information and is not a substitute for a 'diagnosis' of whether one has cancer as a medical act. A low-risk result does not mean that one is cancer-free or will not get cancer in the future.

* Ovarian and breast cancer tests are for women only; prostate cancer test is for men only.

About Craif

Craif is a bio-AI startup founded in 2018 dedicated to the early detection of cancer. By combining its proprietary 'NANO IP® (NANO Intelligence Platform)'—a technology base for high-precision detection of various biomarkers such as DNA and microRNA from bodily fluids like urine—with AI technology, Craif develops innovative tests that enable ultra-early detection, early treatment, and early recovery from cancer. By widely delivering the power of biotechnology and AI to society, the company promotes its vision of 'realizing a society where people live to their fullest potential.'

【Company Profile】

Company Name: Craif Inc.

Representative: Ryuichi Onose, Representative Director & CEO

Established: May 2018

Capital: 100 million yen (as of March 1, 2024)

Business: Research and development of next-generation tests for early detection and personalized medicine, mainly in the cancer field; provision of the 'miSignal® series' of urine cancer tests.

Head Office: THE PORTAL iidabashi B1F, 8-30 Shin-Ogawamachi, Shinjuku-ku, Tokyo

URL: https://craif.com/